Watertown Bio Summer Break Quick Hits
Catching up on the latest news as things slow down for the summer.
Neumora's Phase 3 Trial Miss and a Trio of VC Raises
Watertown companies have now raised $245 million in VC funds in 2026
Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market
Plus the initial dosing of Enanta and Avencell's Clinical Trials
ALS TDI moves to Arsenal Yards, Windgap Medical’s Big Pharma Collab, and Watertown’s Q1 fundraising numbers
Plus the initial dosing of Enanta Plus Addgene’s rebrand and Earth Day clean upsAvencell's Clinical Trials
Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp
Join us next week in Charting Watertown’s Life Science Future